Experimental Pill to Treat Parkinson’s Is Safe, Trial Finds

Testing in animals and lab-grown cells suggests the experimental drug could enhance the function of lysosomes within cells.

A black and white headshot of Andrew Carstens
| 2 min read
3D illustration showing neurons inside the brain

© ISTOCK.COM, Dr_Microbe

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

An oral medication aimed at slowing the advance of Parkinson’s disease was well-tolerated in 150 people who took it over 28 days, according to clinical trial results published in Science Translational Medicine on Wednesday (June 8). The trial did not assess whether the drug affected the disease’s progress in humans. However, the study’s authors write that their experiments in animals and in cells suggest that the treatment may correct the dysfunction in cellular lysosomes that causes the disease.

“This is a very, very important step forward,” Patrick Lewis, a neuroscientist at the University of London’s Royal Veterinary College who was not involved in the research, tells Science.

Parkinson’s disease can occur when LRRK2 enzymes in the brain accumulate at such high levels that they damage lysosomes, organelles that remove toxins from the brain, reports the Financial Times. “Lysosomes perform a garbage disposal and recycling role for cells,” Carole Ho, Denali’s chief medical officer, tells the Financial Times. “If they are not working properly, toxic proteins build up and interfere with the proper functioning of cells in the brain.”

Denali Therapeutics has developed two drugs, DNL201 and DNL151, that work by preventing the buildup of LRRK2 enzymes.

Previous tests of the experimental drugs raised concerns about potential side effects in humans, according to Science: animals given DNL201 displayed high levels of the protein dardarin, which caused the vesicles—small fluid-filled sacs inside cells—in their lungs and kidneys to swell.

The current study aimed to reduce the effects of dardarin build-up while preserving the therapeutic benefit of restoring lysosome function, according to Science. While the small study, which included mice, rats, macaque monkeys, and humans, did not evaluate the efficacy of DNL201 in slowing Parkinson’s, the study demonstrated that the drug boosted lysosomal function in animal models and didn’t cause noticeable side effects in humans or monkeys.

Because DNL201 has to be taken twice daily, Denali has decided to move forward with its companion drug, DNL151, which only requires a single daily dose, reports Science.

“It is a very exciting time for Parkinson’s research as we have now reached the point of clinically testing novel treatments that have been developed based on a better understanding of the underlying biology,” Simon Scott, deputy research director at Cure Parkinson’s, tells the Financial Times.

Keywords

Meet the Author

  • A black and white headshot of Andrew Carstens

    Andy Carstens

    Andy Carstens is a current contributor and past intern at The Scientist. He has a bachelor’s degree in chemical engineering from the Georgia Institute of Technology and a master’s in science writing from Johns Hopkins University. Andy’s work has also appeared in Audubon, Slate, Them, and Aidsmap.
Share
You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio